A study of another anti-OX40 antibody [50], GBR 830, showed significant clinical improvement in patients with moderate to severe atopic dermatitis, together with decreases from the baseline in OX40-expressing T cell and OX40L-expressing dendritic cells in lesional skin. The gene discussed is TNFSF4; the disease is atopic eczema.